Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system.
1. Intact absorption of the bioactive dipeptide Val-Tyr (VY), with in vivo antihypertensive ability in normotensive human subjects, was investigated. 2. As a result of a single oral administration of VY, the VY absorption curve occurred maximally over the second hour postprandially; a greater than 10-fold higher increment of VY following a dose of 12 mg was observed in the plasma at 2 h compared with the baseline concentration of VY at 0 h (1934 +/- 145 vs 159 +/- 11 fmol/mL plasma, respectively). 3. Plasma VY levels increased with dose administered (3, 6 and 12 mg), suggesting that exogenous VY could be absorbed intact into the human blood depending on the dose. The elimination half time (t1/2) of VY was estimated to be 3.1 h. The area under the curve for the 12 mg VY dose was 9185 +/- 688 fmol small middle doth/mL plasma.
Matsui
Toshiro
T
Division of Bioscience and Bioenvironmental Sciences, Faculty of Agriculture, Graduate School, Kyushu University, Fukuoka, Japan. tmatsui@agr.kyushu-u.ac.jp
Tamaya
Kei
K
Seki
Eiji
E
Osajima
Katsuhiro
K
Matsumoto
Kiyoshi
K
Kawasaki
Terukazu
T
D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000803:Angiotensin I / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001775:Blood Circulation / Q000187:drug effects / Q000502:physiology*; D004151:Dipeptides / Q000008:administration & dosage / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male
D000959:Antihypertensive Agents; D004151:Dipeptides; C414029:valyltyrosine; D000804:Angiotensin II; D000450:Aldosterone; D000803:Angiotensin I